SHENZEN, CHINA, May 14 /PRNewswire-FirstCall/ - Hard to Treat
Diseases, Inc. (HTDS; http://www.htdsmedical.com) and the company's
IR representative Mina Mar Marketing Group
(http://www.minamargroup.net/) announce, that the company completed
its Quarterly Reports.
Hard to Treat Diseases, Inc. publishes this Quarterly Report to
serve the company's followers, investors and the public as a
guidance through the past events and possible outcomes of these
events in the upcoming quarter(s). The goal of this Quarterly
Report is to inform about the activities and business achievements
accomplished by Hard to Treat Diseases, Inc. during the
January 1 - March 30, 2010 period.
This report assembles and summarizes all developments realized
during this time period.
The report is now available on the company's IR's website
(http://www.minamargroup.net/) and on Pink Sheets under
Filings.
In other news and events, There appears to be some confussion
about HTDS Melem Secrets web site with some of HTDS critics trying
to confuse new or novice shareholders. The official web site for
HTDS Melem Secrets is www.melemsecrets.com The company can not
comment on any other web sites that sell similar producs as Melem
Secrets. The company has posted its financial reports on its web
site www.htds/medical.com The company will shortly subscribe to
Pink Sheets and begin filing on Pink Sheets.
The company reminds its shareholders and followers to monitor
PinkSheets.com Filing section and also our IR company web site
section "PRESS RELEASES AND FILINGS" TAB
http://www.minamargroup.net/ for non newsworthy corporate
updates.
For any matters relating to retail investor queries or to send
the company or its IR a message please click on the "INVESTOR
SUPPORT" TAB, or the direct link
http://www.minamargroup.net/helpdesk. In this regard, Mina Mar
Group works diligently to answer and address all the pressing
issues regarding its clients to the shareholders' satisfaction. MMG
is in constant contact with the companies, addressing, obtaining
and processing all inquiries. MMG is often one of the advisors or
IR companies utilized by the issuer. Depending on the location of
the issuer and management's availability, it may take up to several
days to address any pressing issues. In a normal course of business
and a pending transaction, the issuer may opt to remain silent in
order not to lose advantage to a competitor. MMG is mindful that
sometimes shareholders want answers immediately, which for the
above reasons cannot be fulfilled on a timely basis.
Don't be a victim. Report a stock basher to authorities. The
company is mindful that short sellers, the company competitors and
stock bashers stalk small cap Pink Sheets listed companies with
hidden agendas. Visit http://www.stockbasher.com/ and find out what
criminal and civil actions the US authorities are taking against
web sites like investorshub.com and other posters, and the remedies
available to you as an individual investor. MMG encourages the
readers to visit this investorshub.com blog and similar "investors"
web sites with an open mind. Discover for yourself why and how
USA based small businesses and the
backbone of the economy suffer. Stay informed and do not allow
entrepreneurs dreams, innovations, and their access to capital to
be thwarted as "scalpers" and day traders vigorously day in and day
out try to exploit and extinguish US innovation and progress for
quick profits.
Filings for this event are currently being reviewed and will be
filed with Pink Sheets and Client Support section in due course. To
be included in company's email database for press releases,
industry updates, and non-weekly activity in the company that may
or may not be news released, please subscribe or opt in mailer at
http://www.minamargroup.com/updates.
Safe Harbor Statement
Information in this news release may contain statements about
future expectations, plans, prospects or performance of Hard to
Treat Diseases, Inc. that constitute forward-looking statements for
purposes of the Safe Harbor Provisions under the Private Securities
Litigation Reform Act of 1995. The words or phrases "can be",
"expects", "may affect", "believed", "estimate", "project" and
similar words and phrases are intended to identify such
forward-looking statements. Hard to Treat Diseases, Inc. cautions
you that any forward-looking information provided by or on behalf
of Hard to Treat Diseases, Inc. is not a guarantee of future
performance. None of the information in this press release
constitutes or is intended as an offer to sell securities or
investment advice of any kind. Hard to Treat Diseases, Inc.'s
actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important
factors, some of which are beyond Hard to Treat Diseases, Inc.'s
control. In addition to those discussed in Hard to Treat Diseases,
Inc.'s press releases, public filings, and statements by Hard to
Treat Diseases, Inc.'s management, including, but not limited to,
Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its
existing capital resources, Hard to Treat Diseases, Inc.'s ability
to raise additional capital to fund future operations, Hard to
Treat Diseases, Inc.'s ability to repay its existing indebtedness,
the uncertainties involved in estimating market opportunities, and
in identifying contracts which match Hard to Treat Diseases, Inc.'s
capability to be awarded contracts. All such forward-looking
statements are current only as of the date on which such statements
were made. Hard to Treat Diseases, Inc. does not undertake any
obligation to publicly update any forward-looking statement to
reflect events or circumstances after the date on which any such
statement is made or to reflect the occurrence of unanticipated
events.
CONTACT: For any investor relations matters, please contact
www.minamargroup.net/helpdesk; Investor Relations Department
Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate
Matters, www.minamargroup.com
SOURCE Hard to Treat Diseases